CHIARINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.859
EU - Europa 897
AS - Asia 874
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 3.634
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.855
SG - Singapore 444
IT - Italia 280
HK - Hong Kong 219
SE - Svezia 160
GB - Regno Unito 147
CN - Cina 128
RU - Federazione Russa 82
ID - Indonesia 66
LT - Lituania 52
DE - Germania 42
FI - Finlandia 38
NL - Olanda 32
IE - Irlanda 30
FR - Francia 8
BG - Bulgaria 4
CZ - Repubblica Ceca 4
JP - Giappone 4
UA - Ucraina 4
ES - Italia 3
RO - Romania 3
TR - Turchia 3
CA - Canada 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BE - Belgio 1
GE - Georgia 1
IN - India 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 3.634
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.071
Singapore 357
Ashburn 269
Hong Kong 217
Nyköping 145
Jakarta 66
Chandler 58
Fairfield 56
London 42
Moscow 39
Houston 37
Helsinki 34
Woodbridge 32
Dublin 30
Southend 30
Parma 29
Bologna 26
Milan 23
Shanghai 23
Amsterdam 20
Beijing 20
Cambridge 19
Seattle 17
Reggio Emilia 16
Wilmington 16
Modena 12
Munich 12
Washington 12
Dallas 11
Kilburn 11
Padova 10
Chiswick 9
Rome 9
Ann Arbor 8
Assago 8
New York 8
San Diego 8
Ferrara 7
Hounslow 7
Islington 7
Naples 7
Torre del Greco 7
Glasgow 6
Carpi 5
Dearborn 5
Frankfurt am Main 5
Arceto 4
Brno 4
Jacksonville 4
Los Angeles 4
Prescot 4
Princeton 4
Sofia 4
Wuhan 4
Boardman 3
Catania 3
Chicago 3
Eugene 3
Guangzhou 3
Lappeenranta 3
Paris 3
Perugia 3
Romola 3
Southwark 3
Venice 3
Aberdare 2
Asaka 2
Bloomington 2
Brentford 2
Curtatone 2
Dong Ket 2
Falls Church 2
Frattamaggiore 2
Giuliano di Roma 2
Gualtieri 2
Izmir 2
La Spezia 2
Madrid 2
Montecatini Terme 2
Newark 2
Pescara 2
Portici 2
Ravenna 2
Rimini 2
Roncoferraro 2
Stockholm 2
Turin 2
Urbino 2
Wandsworth 2
Zhengzhou 2
Acton 1
Andover 1
Auckland 1
Baku 1
Bilbao 1
Bonn 1
Bonndorf 1
Bratislava 1
Bremen 1
Brescello 1
Totale 2.991
Salva come PNG Salva come JPEG
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 225
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 153
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 149
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 108
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 90
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 78
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 60
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 53
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 48
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 47
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 47
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 44
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 43
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 43
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 42
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 42
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 42
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 42
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 42
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 42
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 42
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 42
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 41
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 40
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 39
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 39
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 39
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 38
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 37
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 37
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 37
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 37
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 37
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 37
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 37
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 36
Current treatment strategies for inhibiting mTOR in cancer 36
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 36
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 36
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 36
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 35
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 35
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 35
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 35
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 35
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 35
Therapeutic targeting of CK2 in acute and chronic leukemias 34
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 34
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 34
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 33
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 33
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 33
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 33
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 33
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 32
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 32
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 31
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 31
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 31
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 31
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 31
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 30
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 30
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 30
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 29
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 28
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 28
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 28
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias 28
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 28
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 27
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 27
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 27
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 27
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 27
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 27
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 27
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 27
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 27
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 26
GSK-3: a multifaceted player in acute leukemias 26
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 26
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 26
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 25
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 25
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 25
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 24
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 24
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 24
Advances in Targeting Signal Transduction Pathways 6
Totale 3.654
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.270
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202067 0 0 0 0 0 14 14 10 8 7 7 7
2020/2021132 8 5 10 14 5 19 12 15 10 7 14 13
2021/202290 3 6 4 13 2 4 8 7 8 7 18 10
2022/2023551 7 11 12 27 42 70 30 62 102 26 59 103
2023/2024909 35 28 42 150 125 66 177 62 26 28 87 83
2024/20251.825 88 19 13 231 877 597 0 0 0 0 0 0
Totale 3.654